STOCK TITAN
  1. Home
  2. News
  3. PAVMZ

PAVmed Inc - PAVMZ STOCK NEWS

Welcome to our dedicated news page for PAVmed (Ticker: PAVMZ), a resource for investors and traders seeking the latest updates and insights on PAVmed.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PAVmed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PAVmed's position in the market.

News
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) has announced the publication of three clinical utility studies demonstrating the real-world clinical utility of Lucid's EsoGuard Esophageal DNA test to detect esophageal precancer. The studies document near-perfect concordance between EsoGuard results and the prescribing physician's decision whether to refer patients for upper endoscopy, with 100 percent of EsoGuard-positive patients being referred for confirmatory upper endoscopy. These results eliminate the need for hundreds of costly, invasive, and inconvenient endoscopies, demonstrating that EsoGuard allows physicians to appropriately triage at-risk patients, consistent with established professional society guidelines, and ensure cost-effective utilization of endoscopy in esophageal precancer detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
-
News
PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders
Rhea-AI Summary
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announces the distribution of approximately 3.3 million shares of Lucid common stock to its shareholders as of January 15, 2024. Each PAVmed shareholder will receive a stock dividend of approximately 41 shares of Lucid common stock for every 100 shares of PAVmed common stock they own as of the record date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
-
News
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
Rhea-AI Summary
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announces a dividend of approximately 3.3 million shares of Lucid Diagnostics Inc. (Nasdaq: LUCD) common stock and a 1-for-15 reverse stock split to be effective as of market open on December 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
dividends
News
Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) strengthens its executive team with two industry veterans, Natalie S. Carfora and James M. Fricchione, joining as Vice President, Market Access, and Vice President, Employer Markets, respectively. Shaun M. O'Neil is promoted to President and COO. These appointments aim to drive EsoGuard® payor coverage and secure direct contracts with employers and self-insured entities, crucial for translating test volume growth into revenue. Natalie Carfora brings over a decade of experience in market access and sales, while Jim Fricchione has over two decades of national health benefits experience. Shaun O'Neil, an industry veteran, has been instrumental in designing and building Lucid's commercial infrastructure and overseeing its commercial strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
-
News
PAVmed Provides Business Update and Third Quarter Financial Results
Rhea-AI Summary
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) reported a 392% sequential increase in Lucid's quarterly revenue, with Veris Health's expansion efforts underway. The quarterly financial results were presented, and a webcast is scheduled for tomorrow at 8:30 AM EST.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
earnings
-
News
Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) reports a 17% increase in Quarterly EsoGuard® test volume and a 392% increase in revenue sequentially. The company's CLIA-certified clinical laboratory performed 2,575 commercial EsoGuard® Esophageal DNA Tests in Q3 2023. Lucid's Q3 revenue was $783K, with operating expenses of $11.9 million. Lucid had cash and cash equivalents of $24.1 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.07%
Tags
earnings
News
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day
Rhea-AI Summary
LUCD - Lucid Diagnostics Inc. (Nasdaq: LUCD) announced the launch of EsoGuard 2.0, an enhanced esophageal DNA test with improved performance and lower costs. The company will also host an Investor Day event in New York City on December 13, 2023, to discuss commercial progress and the recent expansion of clinical utility and validity data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
Rhea-AI Summary
Lucid Diagnostics Inc., a cancer prevention medical diagnostics company, announced that its Chairman and CEO, Dr. Lishan Aklog, will present at the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 16, 2023, in New York City. The presentation will take place at 10:00am EST, and management will be available for one-on-one meetings with investors at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
conferences
-
News
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023
Rhea-AI Summary
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) will host a business update conference call and webcast on November 15, 2023, at 8:30 AM EST. The call will provide a business update and overview of operations and growth strategy by Lishan Aklog, M.D., Chairman and CEO. Dennis McGrath, President and CFO, will discuss the third-quarter 2023 financial results. The webcast will be available on the company's website. Replay will be available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
News
Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection
Rhea-AI Summary
Lucid Diagnostics Inc. announces two clinical registries collecting real-world data on EsoGuard testing for esophageal precancer. Initial analysis shows excellent concordance with medical decision-making and over 99% technical success. The registries aim to enroll a substantial proportion of all patients undergoing EsoGuard testing and provide valuable clinical utility and validity data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock PAVMZ logo
PAVmed Inc

Nasdaq:PAVMZ

PAVMZ Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

PAVMZ Stock Data

8.08M
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
New York

About PAVMZ

pavmed is a groundbreaking medical device company bringing innovative medical technologies from concept to commercialization with unprecedented speed and efficiency. led by three accomplished medical device entrepreneurs and organized to conceive, develop and commercialize a diversified pipeline of innovative products we believe address unmet clinical needs, our goal is to enhance and accelerate value creation by employing a business model focused on capital and time efficiency.